Basking Biosciences Administers Initial Dosage to Participants in Phase 2 Study of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke.

In the field of anti-tumor drugs, both monoclonal antibodies (mAbs) and bispecific antibodies (biAbs) are important therapeutic tools.

TILT Biotherapeutics Unveils TILT-123 Clinical Results After Complete IV Administration at ESMO 2024.

The global HIV drug market is highly competitive, with multiple pharmaceutical companies collaborating in research and commercialization to provide more effective treatment options.

Relay Therapeutics has announced encouraging interim results for RLY-2608, the initial investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.

Positive Phase III Results for Akeso's Ivonescimab in First-Line NSCLC Treatment Revealed at 25th WCLC.

These findings showcase the efficacy of its innovative EVX-B2 mRNA Gonorrhea vaccine candidate in eradicating gonorrhea bacteria through the induction of a specialized immune response.

ArriVent BioPharma and Allist Pharmaceuticals unveiled groundbreaking data from their global Phase Ib proof-of-concept randomized study (FURTHER) at the IASCLC 2024 WCLC.

Terns Pharmaceuticals Reports Successful Phase 1 Results for TERN-601 Daily Oral GLP-1R Agonist in Obesity Treatment.

The Synapse database immediately launched a search portal for ESMO clinical results data, facilitating user access.

The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.

Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.